ASH22 could be IL-18’s watershed moment

Going after an old GSK target in a new way, a Yale spinout hits the clinic and nabs a modest raise

Engineering a better immunotherapy to outwit cancer — and launch a biotech

Simcha debuts with $25M to advance custom-built IL-18 for cancer

MENU